2026年11月3日星期二
M
Hoàn Vũ Thông Giám
Tin nhanh toàn cầu
Vietnam solar success prompts rethink of power pricing— 日经 Nikkei AsiaGlobal legal body opens Hong Kong office, boosts city's law hub push— 日经 Nikkei AsiaWill Japanese insurers bring money home? 5 things to know— 日经 Nikkei AsiaChinese steel industry losses snowball as demand falls and costs rise— 日经 Nikkei AsiaSurging costs and China trade war test US farmers' loyalty to Trump— 日经 Nikkei AsiaBangladesh turns to China for worker training amid graduate job struggles— 日经 Nikkei AsiaMyanmar refugees fill labor gaps in Thailand as Cambodians return home— 日经 Nikkei AsiaOriental Kopi founder wants to put Malaysia on the menu— 日经 Nikkei AsiaVietnam solar success prompts rethink of power pricing— 日经 Nikkei AsiaGlobal legal body opens Hong Kong office, boosts city's law hub push— 日经 Nikkei AsiaWill Japanese insurers bring money home? 5 things to know— 日经 Nikkei AsiaChinese steel industry losses snowball as demand falls and costs rise— 日经 Nikkei AsiaSurging costs and China trade war test US farmers' loyalty to Trump— 日经 Nikkei AsiaBangladesh turns to China for worker training amid graduate job struggles— 日经 Nikkei AsiaMyanmar refugees fill labor gaps in Thailand as Cambodians return home— 日经 Nikkei AsiaOriental Kopi founder wants to put Malaysia on the menu— 日经 Nikkei Asia

5-year outcomes of chemotherapy de-escalation in HER2-positive early breast cancer and exploratory circulating tumor DNA analyses from the randomized phase 2 PHERGain trial

Nguồn Nature 医学研究4 ngày trước
Tóm tắt nội dung

Trang này chỉ cung cấp tiêu đề và chỉ mục tóm tắt, toàn bộ nội dung và bản quyền đều thuộc về bên phát hành gốc, vui lòng nhấp vào liên kết gốc để đọc.

Đi tới bài gốc
Kênh trực thuộc
Sức khỏe
Khu vực trực thuộc
Góc nhìn toàn cầu
Ngôn ngữ gốc
English
Số mục
health-a97f47b5

Comments 0 comments

No comments yet. Be the first.

5-year outcomes of chemotherapy de-escalation in HER2-positive early breast cancer and exploratory circulating tumor DNA analyses from the randomized phase 2 PHERGain trial · Hoàn Vũ Thông Giám